ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that the Company’s novel anti-cancer drug, Archexin™, has been selected as one of the Top 10 most promising oncology products in development that is available for strategic partnering.
